GGO Vergunningendatabase

Zoekcriteria
Zoekresultaat
C/NL/06/01_001 Suntory Flowers Limited Application for renewal of consent for marketing approval under Directive 2001/18/EC (Event FLORIGENE®Moonaqua™(FLO-4Ø689-6)) 09-11-2018 Vergunning verleend
C/NL/13/02/00 Suntory Holdings Application to import cut-flowers of carnation (Dianthus caryophyllus) line FLO-40685-2 for distribution and retail under directive 2001/18/EC 05-09-2019 Vergunning verleend
IM 11-003_009 LUMC Toediening van donor virus-specifieke T-cellen die ex vivo getransduceerd zijn met een retrovirale vector coderend voor leukemie-specifieke TCR, als behandeling na allogene stamceltransplantatie voor patiënten met refractaire of recidief hematologische maligniteiten 28-08-2019 Vergunning verleend
IM-MV 18-014_000 LUMC RAG1‐SCID and RAG2‐SCID CD34+ gene therapy using 3rd generation self‐inactivating (SIN)‐lentiviral vector 16-08-2019 Vergunning verleend
IM-MV 19-004_000 Erasmus MC Clinical testing of MC2 TCR T cells, an autologous cellular immunotherapy composed of autologous T cells genetically modified ex vivo to express a T cell receptor (TCR) that, upon reinfusion into the patient, recognize and kill MAGE-C2 (MC2)-expressing tumor cells 27-08-2019 Vergunning verleend
IM-MV 19-005_000 Erasmus MC Phase III study testing bb2121, consisting of autologous T lymphocytes ex-vivo transduced by a replication-defective lentiviral vector to express anti-BCMA chimeric antigen receptors (CAR) to target tumor cells expressing the human B cell maturation antigen (BCMA), in patients with relapsed and refractory multiple myeloma (RRMM) 16-08-2019 Vergunning verleend
IM-MV 19-008_000 Het Nederlands Kanker Instituut Clinical Trials to Assess the Safety and/or Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells (GSK3377794), alone or in combination with other agents, in HLA-A*02:01, HLA-A*02:05 and/or HLA-A*02:06 Participants with NY-ESO-1 and/or LAGE-1a Positive Cancers Ontwerpbesluit genomen
IM-MV 19-009_000 Erasmus MC A Phase III, Open-Label, Randomized, Parallel Group Study to Evaluate the Efficacy and Safety of Intrapleural Administration of adenovirus-Delivered Interferon Alpha-2b (rAd-IFN) in Patients with Malignant Pleural Mesothelioma Ontwerpbesluit genomen
IM-MV 19-010_000 Universitair Medisch Centrum Utrecht A Randomized, Placebo-Controlled, Phase 2 Study of HB-101, a Bivalent Cytomegalovirus (CMV) Vaccine, in CMV-seronegative Recipient (R-) Patients Awaiting Kidney Transplantation from Living CMV-seropositive Donors (D+) 27-08-2019 Vergunning verleend
IM-MV 19-011_000 Erasmus MC Clinical testing of JNJ-68284528, composed of autologous T cells genetically modified with a lentiviral vector (LVV) to express a chimeric antigen receptor (CAR) that, upon reinfusion into the patient, recognize and kill B-cell maturation antigen (BCMA)-expressing tumour cells 04-09-2019 Vergunning verleend
IM-MV 19-012_000 VU medisch centrum Clinical testing of JNJ-68284528, composed of autologous T cells genetically modified with a lentiviral vector (LVV) to express a chimeric antigen receptor (CAR) that, upon reinfusion into the patient, recognize and kill B-cell maturation antigen (BCMA)-expressing tumor cells 04-09-2019 Vergunning verleend
IM-MV 19-013_000 LUMC A Randomized, Placebo-Controlled, Phase 2 Study of HB-101, a Bivalent Cytomegalovirus (CMV) Vaccine, in CMV-seronegative Recipient (R-) Patients Awaiting Kidney Transplantation from Living CMV-seropositive Donors (D+) 28-08-2019 Vergunning verleend
IM-MV 19-015_000 VU medisch centrum Clinical trials testing bb2121, consisting of autologous T lymphocytes ex-vivo transduced by a replication-defective lentiviral vector to express anti-BCMA chimeric antigen receptors (CAR) to target tumor cells expressing the human B cell maturation antigen (BCMA), in patients with multiple myeloma Ontwerpbesluit genomen
IM-MV 19-017_000 Universitair Medisch Centrum Utrecht Clinical Trials to Assess the Safety and/or Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells (GSK3377794), alone or in combination with other agents, in HLA-A*02:01, HLA-A*02:05 and/or HLA-A*02:06 Participants with NY-ESO-1 and/or LAGE-1a Positive Cancers Ontwerpbesluit genomen